What question did this study set out to answer?

To review the biochemistry and physiology of proteasome inhibition and assess clinical evidence for proteasome inhibitor therapy in transplant rejection.

November 17, 2009Current Opinion in Organ Transplantation

Proteasome inhibition for antibody-mediated rejection

View Full Paper

Ask AI

Bookmark

Authors

JEJ Everly RWR. C. Walsh RARita R. Alloway

Discussion

Member takes

Overview

Review reveals proteasome inhibition depletes plasma cells and reduces donor-specific antibodies in kidney transplant recipients, indicating a potential targeted therapy for graft rejection.

Key Points

To review the biochemistry and physiology of proteasome inhibition and assess clinical evidence for proteasome inhibitor therapy in transplant rejection.
Synthesized mechanistic and clinical literature on proteasome inhibition in animal models and human organ transplant recipients.
Evaluated outcomes associated with bortezomib therapy, focusing on plasma cell depletion, anti-human leukocyte antigen (HLA) antibody levels, and graft histology.
Bortezomib eliminates transformed and nontransformed plasma cells, which typically resist conventional antihumoral immunosuppression.
Proteasome inhibitor treatment reduces donor-specific anti-HLA antibody titers and reverses histological rejection features in kidney allograft recipients.
Depletion of antibody-producing plasma cells and reductions in donor-specific antibodies occur in both active antibody-mediated rejection and rejection-free settings.

Cite This Study

Everly et al. (2009) studied this question.

synapsesocial.com/papers/6a7268e82fdcb5703edb9019 https://doi.org/10.1097/mot.0b013e328330f304

View Full Paper

Ask AI

Bookmark

November 17, 2009Current Opinion in Organ Transplantation

Proteasome inhibition for antibody-mediated rejection

View Full Paper

Ask AI

Bookmark

Authors

JEJ Everly RWR. C. Walsh RARita R. Alloway

Discussion

Member takes

Overview

Review reveals proteasome inhibition depletes plasma cells and reduces donor-specific antibodies in kidney transplant recipients, indicating a potential targeted therapy for graft rejection.

Key Points

To review the biochemistry and physiology of proteasome inhibition and assess clinical evidence for proteasome inhibitor therapy in transplant rejection.
Synthesized mechanistic and clinical literature on proteasome inhibition in animal models and human organ transplant recipients.
Evaluated outcomes associated with bortezomib therapy, focusing on plasma cell depletion, anti-human leukocyte antigen (HLA) antibody levels, and graft histology.
Bortezomib eliminates transformed and nontransformed plasma cells, which typically resist conventional antihumoral immunosuppression.
Proteasome inhibitor treatment reduces donor-specific anti-HLA antibody titers and reverses histological rejection features in kidney allograft recipients.
Depletion of antibody-producing plasma cells and reductions in donor-specific antibodies occur in both active antibody-mediated rejection and rejection-free settings.

Cite This Study

Everly et al. (2009) studied this question.

synapsesocial.com/papers/6a7268e82fdcb5703edb9019 https://doi.org/10.1097/mot.0b013e328330f304

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark